MSKCC Investigator-Initiated Clinical Trial Agreement with Kazia Therapeutics LimitedKazia Therapeutics Limited • October 22nd, 2020 • Kazia Therapeutics LTD • Pharmaceutical preparations • New York
This Agreement (this “Agreement”), effective as of the date of the last signature (“Effective Date”), is entered into by Memorial Sloan Kettering Cancer Center, a New York not-for-profit corporation (“MSK”), having its principal place of business at 1275 York Avenue, New York, NY 10065, on behalf of Memorial Hospital for Cancer and Allied Diseases and its Regional Sites (collectively, “MSK”), and Kazia Therapeutics Limited, a drug development company, with its principal office and place of business at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000, Australia (“Company”). MSK and Company may each be referred to as a “Party” to this Agreement, and referred to collectively as the “Parties.”
